Cevostamab

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

More Information

Trial Status
Not currently accepting
Trial Phase
Phase 1
Enrollment
420 patients (estimated)
Sponsors
Genentech
Tags
Bispecific Antibody, FCRH5
Trial Type
Treatment
Last Update
2 weeks ago
SparkCures ID
908
NCT Identifier
NCT03275103

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.